EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors
Andrology · 2025
DOI: 10.1111/andr.13604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Andrology, 2025. Verfasst von Helena Estevão-Pereira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Background
Testicular germ cell tumors remain the most frequent solid malignancies in young males. Despite excellent prognosis, the fact that only 60% of patients at diagnosis have elevated serum tumor markers (dependent on stage and histology) and the poor quality of life of patients who develop resistance to chemotherapy cannot be neglected. Consequently, it is mandatory to bring out novel biomarkers.
Objectives
The main goal was to evaluate EZH2 and EHMT2/G9a immunoexpression in a well‐characterized patients’ cohort of primary and metastatic testicular germ cell tumors, seeking associations with clinicopathological features and discovering differential immunoexpression patterns among specific subtypes. Materials and methods First, an in silico analysis of the Cancer Genome Atlas database was performed regarding EZH2 and EHMT2/G9a. Then, immunohistochemistry for EZH2 and EHMT2/G9a was carried out in a cohort of testicular germ cell tumor patients, comprising 155 chemo‐naïve primary tumors and 11 chemo‐treated metastases. Immunoexpression was evaluated using a digital pathology analysis software.
Results
Higher EZH2 and EHMT2/G9a expression levels were found in non‐seminoma in the in silico analysis, particularly in embryonal carcinoma. Through digital pathology analysis, non‐seminomas showed significantly higher EZH2 and EHMT2/G9a immunoexpression, with embryonal carcinoma showing higher expression. Moreover, mixed tumors with 50% or more of embryonal carcinoma component revealed the highest nuclei positivity for both biomarkers. Cisplatin‐exposed metastases demonstrated a higher EZH2‐positive nuclei and H ‐score, as well as higher EHMT2/G9a‐positive nuclei. Discussion and conclusion Overall, our data suggest that EZH2 and EHMT2/G9a might be associated with greater aggressiveness and, eventually, involved in the metastatic setting, paving the way for testing targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Po…
- Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
- Department of Urology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
- Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal.
- Clinical Oncology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raque…
- Department of Pathology and Molecular Immunology, ICBAS - School of Medicine & Biomedical Sciences, University of Porto, Porto, Portugal.
ORCID-Profile: Rui Henrique, João Lobo
Förderung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Estevão-Pereira, H., Guimarães-Teixeira, C., Flores, B. C. T., Moreira-Silva, F., Tavares, N. T., Guimarães, R., Braga, I., Maurício, J., Henrique, R., Jerónimo, C., & Lobo, J. (2025). EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors. Andrology. https://doi.org/10.1111/andr.13604
Vancouver
Estevão-Pereira H, Guimarães-Teixeira C, Flores BCT, Moreira-Silva F, Tavares NT, Guimarães R, et al. EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors. Andrology. 2025. doi:10.1111/andr.13604
BibTeX
@article{EstevoPereira2025,
author = {Estevão-Pereira, Helena and Guimarães-Teixeira, Catarina and Flores, Bianca C T and Moreira-Silva, Filipa and Tavares, Nuno Tiago and Guimarães, Rita and Braga, Isaac and Maurício, Joaquina and Henrique, Rui and Jerónimo, Carmen and Lobo, João},
title = {EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors},
journal = {Andrology},
year = {2025},
doi = {10.1111/andr.13604}
}
EUVIMED